

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – November 6, 2006

NOTICE OF STATUS CHANGE

Study 2 is temporarily suspended effective Monday, November 6, 2006.
Accrual to dose level 3E has been met.

Please retain this notice with the protocol.